T. Rowe Price Investment Management, Inc. Karuna Therapeutics, Inc. Transaction History

T. Rowe Price Investment Management, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$161.01 - $317.85 $5.29 Million - $10.4 Million	-32,828 Reduced 1.2%	2,709,629 $858 Million
Q3 2023 Nov 14, 2023	BUY	$164.66 - $218.08 $43.4 Million - $57.4 Million	263,422 Added 10.63%	2,742,457 $464 Million
Q2 2023 Aug 14, 2023	SELL	$176.32 - $240.22 $305,033 - $415,580	-1,730 Reduced 0.07%	2,479,035 $538 Million
Q1 2023 May 15, 2023	BUY	$161.33 - $204.36 $206 Million - $261 Million	1,278,134 Added 106.28%	2,480,765 $451 Million
Q4 2022 Feb 14, 2023	BUY	$191.53 - $236.82 $43.9 Million - $54.3 Million	229,374 Added 23.57%	1,202,631 $236 Million
Q3 2022 Nov 14, 2022	BUY	$123.79 - $277.42 $120 Million - $270 Million	973,257 New	973,257 $219 Million

332K

Ticker KRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 33,965,000
Description
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.